卵巢癌术后恩度腹腔灌注联合静脉化疗的临床观察

Clinical efficacy of Endostar intraperitoneal perfusion combined with intravenous chemotherapy for ovarian cancer

目的:探讨卵巢癌术后重组人血管内皮抑制素(恩度)腹腔灌注联合TC方案静脉化疗的近期疗效、毒副反应及生存率。方法:将我院2010年3月至2012年1月收治的86例卵巢癌术后患者,随机单盲分成观察组45例(恩度腹腔灌注联合TC静脉化疗),对照组41例(单纯TC静脉化疗),比较两组近期疗效、毒副反应及生存率。结果:观察组治疗卵巢癌近期缓解率48.9%(22/45)优于对照组26.8%(11/41),两组比较差异有统计学意义(P<0.05);两组毒副反应比较差异无统计学意义(P>0.05)。观察组3年和5年生存率分别为71.1%(32/45)和53.3%(24/45),高于对照组48.8%(20/41)和29.3%(12/41)。两组比较差异有统计学意义(P<0.05)。结论:恩度腹腔灌注联合TC方案静脉化疗可显著提高卵巢癌患者的疗效,改善生存率且不增加毒副作用。

Objectlve：To investigate the clinical efficacy,side effects and overall survival （OS） rates of Endostar intraperitoneal perfusion combined with intravenous chemotherapy for ovarian cancer. Methods：From March 2010 to January 2012, the data of 45 patients （observation group） were treated with Endostar intraperitoneal perfusion and in- travenous chemotherapy. 41 patients （control group） were treated with intravenous chemotherapy. The recent efficacy and toxicity and survival rate between the two groups were observed. Results：The response rate 48.9% （22/45） of observation group were significantly better than those of control group 26.8% （ 11/41 ） （P 〈 0.05 ）. There were no sig- nificantly different in toxicity between the two groups （ P 〉 0. 05 ）. The 3 - year and 5 - year survival rates of observa- tion group were 71.1% （32/45） and 53.3% （24/45） respectively, were significantly better than those of control group 48.8 % （ 20/41 ） and 29.3 % （ 12/41 ） （ P 〈 0.05 ）. Conclusion： The Endostar intraperitoneal perfusion and in- travenous chemotherapy can significantly improve the therapeutic effect and OS of ovarian cancer without increasing side effects.